Synthetic Clinical Demo Dataset: All patient records, histories, and outcomes are entirely synthetic and modeled for hospital network research exploration. Not for clinical treatment recommendations.
3C v1.0

Clinical & Epidemiological Insights

Dynamic statistical patterns discovered across longitudinal oncology records

Every insight displays its underlying statistical cohort, exact mathematical calculation, and empirical sample size. Click Explore Cohort on any card to isolate and inspect the matching patients in the interactive cohort builder.

EPIDEMIOLOGYINS-001
98% Statistical Confidence

"Head & neck malignancies account for 28.6% of all synthetic oncology registry cases"

Underlying Cohort: All Registered Cancer Patients (Maharashtra & Gujarat)
Registry Share
28.6%
Sample Count
109 / 381
Proportion
28.6%
Formula: COUNT(Head & Neck episodes: 109) ÷ COUNT(All Cancer Episodes: 381) × 100

Clinical Interpretation: Reflects the high regional epidemiological prevalence of oral cavity and upper aerodigestive tract cancers in Western India associated with smokeless tobacco consumption patterns.

Source: Western India Synthetic Oncology Network
EPIDEMIOLOGYINS-002
96% Statistical Confidence

"Locally advanced Stage III cases represent the single largest group (60.6%) among head & neck patients"

Underlying Cohort: Head & Neck Malignancies Cohort
Stage III Proportion
60.6%
Sample Count
66 / 109
Proportion
60.6%
Formula: COUNT(Stage III Head & Neck cases: 66) ÷ COUNT(Total Head & Neck Cohort: 109) × 100

Clinical Interpretation: Delayed presentation at advanced stages (T3/T4 or N+) highlights the critical necessity of aggressive multimodal intervention and early community screening.

Source: Western India Synthetic Oncology Network
TREATMENT PATTERNSINS-003
95% Statistical Confidence

"52.4% of tongue cancer patients receive combined multimodal therapy (Surgery + Adjuvant CRT)"

Underlying Cohort: Tongue Carcinoma Primary Site Cohort
Multimodal Regimen Share
52.4%
Sample Count
11 / 21
Proportion
52.4%
Formula: COUNT(Tongue patients receiving Surgery + Radiation/Chemotherapy: 11) ÷ COUNT(All Tongue Cancer Patients: 21) × 100

Clinical Interpretation: Adjuvant chemoradiotherapy following primary surgical resection with neck dissection remains the standard of care for high-risk pathological features (positive nodes, perineural invasion).

Source: Western India Synthetic Oncology Network
LONGITUDINAL FOLLOWUPINS-004
99% Statistical Confidence

"24.2% of registered patients have achieved 5+ years of active longitudinal surveillance"

Underlying Cohort: Long-term Surveillance Registry (Diagnosed 2020–2021)
5-Year Surveillance Cohort
92 patients
Sample Count
92 / 380
Proportion
24.2%
Formula: COUNT(Patients with Last Follow-up Year - Diagnosis Year ≥ 5: 92) ÷ Total Registered Patients (380) × 100

Clinical Interpretation: Longitudinal surveillance allows robust real-world survival benchmarking and monitoring for late radiation toxicities or secondary metachronous malignancies.

Source: Western India Synthetic Oncology Network
RECURRENCE RISKINS-005
94% Statistical Confidence

"82% of all documented recurrences occurred within the first 24 months post-diagnosis"

Underlying Cohort: Documented Recurrence Registry
Early Recurrence Clustering (<24m)
82%
Sample Count
50 / 61
Proportion
82%
Formula: COUNT(Recurrences with Interval ≤ 24 months: 50) ÷ COUNT(Total Recurrences: 61) × 100

Clinical Interpretation: Demonstrates that intensive 3-monthly surveillance imaging and clinical evaluations are highest-yield during the first 2 post-treatment years.

Source: Western India Synthetic Oncology Network